MTNB insider filings
Matinas BioPharma Holdings, Inc. — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2026-11-09. Screen MTNB transaction legs live →
Insider transaction summary — last 90 days
2026-08-23 to 2026-11-21, from the filings listed below: 6 insider filings (Forms 3/4/5). Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 6.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| D An Evelyn — Director | 2 | — | — | 2 |
| Murphy Keith — Director | 2 | — | — | 2 |
| NEUGEBOREN EDWARD — Director | 2 | — | — | 2 |
Recent insider filings — Matinas BioPharma Holdings, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-09 | 4/A | D An Evelyn — Director | Grant/award (A): 5,000 (derivative) @ $0 | EDGAR |
| 2026-11-09 | 4/A | NEUGEBOREN EDWARD — Director | Grant/award (A): 5,000 (derivative) @ $0 | EDGAR |
| 2026-11-09 | 4/A | Murphy Keith — Director | Grant/award (A): 5,000 (derivative) @ $0 | EDGAR |
| 2026-11-06 | 4 | NEUGEBOREN EDWARD — Director | Grant/award (A): 5,000 (derivative) @ $0 | EDGAR |
| 2026-11-06 | 4 | D An Evelyn — Director | Grant/award (A): 5,000 (derivative) @ $0 | EDGAR |
| 2026-11-06 | 4 | Murphy Keith — Director | Grant/award (A): 5,000 (derivative) @ $0 | EDGAR |
| 2026-08-13 | 4 | STERN ADAM K — 10% owner | Option exercise/expiry (X): 92,100 @ $0.64 · Option exercise/expiry (X): 344,710 @ $0.35 · Option exercise/expiry (X): 630,335 @ $0.35 · Other (J): 800,000 (derivative) @ $0.64 · Other (J): 265 (derivative) @ $0.59 · Option exercise/expiry (X): 92,100 (derivative) @ $0.64 · +5 more | EDGAR |
| 2026-08-13 | 4 | Sanitam Partners LLC — 10% owner | Other (J): 1,406 (derivative) @ $0.59 · Other (J): 4,798,636 (derivative) @ $0.64 | EDGAR |
| 2025-05-02 | 4 | Jabbour Jerome D — President and CEO, Director | Grant/award (A): 70,100 (derivative) @ $0 | EDGAR |
| 2025-05-02 | 4 | Murphy Keith — Director | Grant/award (A): 11,600 (derivative) @ $0 | EDGAR |
| 2025-05-02 | 4 | Smith Robin L — Director | Grant/award (A): 11,600 (derivative) @ $0 | EDGAR |
| 2025-05-02 | 4 | D An Evelyn — Director | Grant/award (A): 11,600 (derivative) @ $0 | EDGAR |
| 2025-05-02 | 4 | NEUGEBOREN EDWARD — Director | Grant/award (A): 11,600 (derivative) @ $0 | EDGAR |
| 2025-04-10 | 4/A | Sanitam Partners LLC — 10% owner | Purchase (P): 703 (derivative) @ $1,000 · Purchase (P): 2,399,318 (derivative) | EDGAR |
| 2025-04-10 | 4/A | Pembroke & Partners LLC — 10% owner | Purchase (P): 492 (derivative) @ $1,000 · Purchase (P): 1,679,182 (derivative) | EDGAR |
| 2025-04-10 | 4/A | EIDE ROBERT J — 10% owner | Purchase (P): 492 (derivative) @ $1,000 · Purchase (P): 1,679,182 (derivative) | EDGAR |
| 2023-12-15 | 4 | Kucinski Keith A — Chief Financial Officer | Grant/award (A): 1,000,000 (derivative) @ $0 | EDGAR |
| 2023-12-15 | 4 | Liu Hui — Chief Technology Officer | Grant/award (A): 1,000,000 (derivative) @ $0 | EDGAR |
| 2023-12-15 | 4 | Jabbour Jerome D — President and CEO, Director | Grant/award (A): 3,500,000 (derivative) @ $0 | EDGAR |
| 2023-12-15 | 4 | Hoover Thomas — Chief Business Officer | Grant/award (A): 1,000,000 (derivative) @ $0 | EDGAR |
| 2023-12-15 | 4 | Ferguson James J. III — Chief Medical Officer | Grant/award (A): 1,200,000 (derivative) @ $0 | EDGAR |
| 2023-12-15 | 4 | Matkovits Theresa — Chief Development Officer | Grant/award (A): 1,300,000 (derivative) @ $0 | EDGAR |
| 2023-11-03 | 4 | Corzo Kathryn Penkus — Director | Grant/award (A): 437,244 (derivative) @ $0 | EDGAR |
| 2023-11-03 | 4 | Ende Eric J — Director | Grant/award (A): 437,244 (derivative) @ $0 | EDGAR |
| 2023-11-03 | 4 | Scibetta James S — Director | Grant/award (A): 437,244 (derivative) @ $0 | EDGAR |
| 2023-11-03 | 4 | Giordano Natasha — Director | Grant/award (A): 437,244 (derivative) @ $0 | EDGAR |
| 2023-11-03 | 4 | CONRAD HERBERT J — Director | Grant/award (A): 437,244 (derivative) @ $0 | EDGAR |
| 2023-11-03 | 4 | WIKLER MATTHEW — Director | Grant/award (A): 437,244 (derivative) @ $0 | EDGAR |
| 2022-12-22 | 4 | Matkovits Theresa — Chief Development Officer | Grant/award (A): 625,000 (derivative) @ $0 | EDGAR |
| 2022-12-22 | 4 | Liu Hui — Chief Technology Officer | Grant/award (A): 625,000 (derivative) @ $0 | EDGAR |
| 2022-12-22 | 4 | Kucinski Keith A — Chief Financial Officer | Grant/award (A): 625,000 (derivative) @ $0 | EDGAR |
| 2022-12-22 | 4 | Jabbour Jerome D — President and CEO, Director | Grant/award (A): 1,988,300 (derivative) @ $0 | EDGAR |
| 2022-12-22 | 4 | Hoover Thomas — Chief Business Officer | Grant/award (A): 475,000 (derivative) @ $0 | EDGAR |
| 2022-12-22 | 4 | Ferguson James J. III — Chief Medical Officer | Grant/award (A): 625,000 (derivative) @ $0 | EDGAR |
| 2022-11-16 | 4 | Corzo Kathryn Penkus — Director | Grant/award (A): 142,657 (derivative) @ $0 | EDGAR |
| 2022-11-16 | 4 | Ende Eric J — Director | Grant/award (A): 142,657 (derivative) @ $0 | EDGAR |
| 2022-11-16 | 4 | Scibetta James S — Director | Grant/award (A): 142,657 (derivative) @ $0 | EDGAR |
| 2022-11-16 | 4 | Giordano Natasha — Director | Grant/award (A): 142,657 (derivative) @ $0 | EDGAR |
| 2022-11-16 | 4 | CONRAD HERBERT J — Director | Grant/award (A): 142,657 (derivative) @ $0 | EDGAR |
| 2022-11-16 | 4 | WIKLER MATTHEW — Director | Grant/award (A): 142,657 (derivative) @ $0 | EDGAR |
| 2022-07-05 | 4 | CONRAD HERBERT J — Director | Gift (G): 494,622 @ $0 · Gift (G): 494,622 @ $0 · Gift (G): 1,358,122 @ $0 · Gift (G): 1,358,122 @ $0 | EDGAR |
| 2022-01-03 | 4 | WIKLER MATTHEW — Director | Grant/award (A): 7,859 @ $0 | EDGAR |
| 2021-12-15 | 4 | Jabbour Jerome D — President and CEO, Director | Grant/award (A): 1,658,100 (derivative) @ $0 | EDGAR |
| 2021-12-15 | 4 | Kucinski Keith A — Chief Financial Officer | Grant/award (A): 500,000 (derivative) @ $0 | EDGAR |
| 2021-12-15 | 4 | Ferguson James J. III — Chief Medical Officer | Grant/award (A): 587,600 (derivative) @ $0 | EDGAR |
| 2021-12-15 | 4 | Hoover Thomas — Chief Business Officer | Grant/award (A): 850,000 (derivative) @ $0 | EDGAR |
| 2021-12-15 | 4 | Hui Liu — Chief Technology Officer | Grant/award (A): 275,000 (derivative) @ $0 | EDGAR |
| 2021-12-15 | 4 | Matkovits Theresa — Chief Development Officer | Grant/award (A): 500,000 (derivative) @ $0 | EDGAR |
| 2021-12-15 | 4 | MANNINO RAPHAEL J — Chief Scientific Officer | Grant/award (A): 275,000 (derivative) @ $0 | EDGAR |
| 2021-11-02 | 4 | CONRAD HERBERT J — Director | Grant/award (A): 90,882 (derivative) @ $0 | EDGAR |
Recent 8-K events — Matinas BioPharma Holdings, Inc.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-11-03 | 8-K | 8.01 — Other Events | EDGAR |
| 2026-09-28 | 8-K | 3.03 — Material Modification to Rights of Security Holders 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-16 | 8-K | 8.01 — Other Events | EDGAR |
| 2026-09-04 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-24 | 8-K | 1.02 — Termination of a Material Definitive Agreement | EDGAR |
| 2026-07-13 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 3.03 — Material Modification to Rights of Security Holders 5.01 — Changes in Control of Registrant 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-26 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-03 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-23 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2025-12-12 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=MTNB returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs